GRANITE: Airsupra Effectiveness in the Real World
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
4,060actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-09 | actual | When the study began enrolling |
| Primary completion | 2026-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-20 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Intervention
- Other: None (Observational study) — also filed as Observational study
Primary outcomes
what the primary-completion date above is the date OFBaseline demographics and clinical characteristics of patients receiving Airsupra and albuterol
measured Baseline period is 12 months prior to the index date
Severe asthma exacerbations
measured Follow-up period for each patient starts the day after the index date and ends at the earliest date of: end of data period,end of continuous enrolment(after 12 months),switch to albuterol(Airsupra cohort),Airsupra (albuterol cohort),or death.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed